Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 3.19 · opened flat. High/low 3.20 at 6:15 pm ET, 3.19 at 9:30 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On December 12, 2024, we entered into a license and collaboration agreement with Neopharm. Under the terms of the agreement, we granted Neopharm exclusive commercialization rights to NEXLETOL and NEXLIZET in Israel, Gaza, and West Bank.”
FILING10-K0001628280-26-016522cik 0001434868
“Otsuka Pharmaceutical Co., Ltd., or Otsuka, our Japanese collaborator, received approval from the Japanese Ministry of Health, Labour and Welfare to market NEXLETOL as a treatment for hypercholesterolemia and familial hypercholesterolemia in September 2025, with National Health Insurance, or NHI, pricing received in the fourth quarter of 2025.”
FILING10-K0001628280-26-016522cik 0001434868
“On February 26, 2025, we entered into a license and distribution agreement with Seqirus Pty Ltd, or CSL Seqirus, for the rights to commercialize NEXLETOL and NEXLIZET in Australia and New Zealand.”
FILING10-K0001628280-26-016522cik 0001434868
“Collaboration revenue in the year ended December 31, 2024 was primarily related to the Settlement Agreement with DSE, a milestone from Otsuka upon first Japanese New Drug Application, or JNDA, submission in the Otsuka Territory, sales of bulk tablets under supply agreements and royalty revenue received from collaboration partners.”
FILING10-K0001628280-26-016522cik 0001434868
“In April 2008, we entered into an asset transfer agreement with Pfizer pursuant to which we acquired all intellectual property owned by Pfizer relating exclusively to the bempedoic acid program.”
FILING10-K0001628280-26-016522cik 0001434868
“We announced collaboration agreements for the commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablet with DSE in 2019, with Otsuka in 2020, and with Daiichi Sankyo Co. Ltd, or DS, in 2021.”
FILING10-K0001628280-26-016522cik 0001434868
“Collaboration revenue in the year ended December 31, 2025 was primarily related to milestone payments from Otsuka related to NEXLETOL approval in the Otsuka Territory, the first NHI Price Listing for NEXLETOL in the Otsuka Territory, and the achievement of the primary major adverse cardiovascular events, or MACE, endpoint in the CLEAR Outcomes study and inclusion of the CV risk reduction indication in the U.S. label, as well as an upfront milestone payment from HLS Therapeutics Inc., or HLS, sales of bulk tablets under supply agreements and royalty revenue received from collaboration partners.”
FILING10-K0001628280-26-016522cik 0001434868
Watchlist prices, news filtered to it, and its next report on your desk.
Esperion Therapeutics, Inc. has 1 disclosed supplier and 6 disclosed customers. Each one is named in an SEC filing, either Esperion Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Esperion Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
ESPR (Esperion Therapeutics, Inc.) has 1 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PFE −0.67%, in healthcare.